Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...

The results come two months after Merck shared positive results from the phase 3 KEYNOTE-689 trial of Keytruda as a ...

Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines. Click here to check out my ...

Merck, a leading science and technology company, highlighted latest research and improvements in clinical outcomes for multiple sclerosis (MS) at the fifth congress of the Middle East North Africa ...

Merck, Sharp, and Dohme (MSD) has announced it is to build a state of the art life sciences R&D facility in London, creating around 950 jobs. Known as Merck & Co in the US, the company said the ...

Merck to discontinue phase 3 KeyVibe-003 & KeyVibe-007 trials of vibostolimab and favezelimab FDCs with pembrolizumab in certain patients with NSCLC: Rahway, New Jersey Wednesday, ...

US-based pharmaceutical company MSD has published results from a Phase III trial of a potential combination therapy for ovarian cancer.

Merck announces phase 3 KEYLYNK-001 trial meets primary endpoint of PFS in patients with advanced epithelial ovarian cancer: Rahway, New Jersey Tuesday, December 10, 2024, 18:00 H ...

MSD has reported positive topline outcomes from the Phase III MK-3475A ... pembrolizumab compared to its IV counterpart. MSD Research Laboratories oncology, global clinical development head ...

MSD Research Laboratories global clinical development ... for approval of WINREVAIR in Japan based on both the STELLAR study outcomes and an open-label Phase III trial in Japanese subjects.